Posters/Publications

Title
Venue
Type
Date

ASC41, a selective THRβ agonist significantly reduces liver fat and ALT in biopsy-confirmed MASH patients after 12-week treatment: an interim analysis of a 52-week serial liver biopsy study

The European Association for the Study of the Liver (EASL) Congress 2024

Poster

06/2024
ASC41, a thyroid hormone receptor β agonist, showed little drug interaction, significant lipid reduction and comparable pharmacokinetic profiles among Chinese and US healthy subjects and patients with non-alcoholic fatty liver disease (NAFLD): results from two phase 1 studies

The Liver Meeting® 2023 of the American Association for the Study of Liver Diseases (AASLD)

Poster

11/2023
A Phase Ib Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ASC 41 a THR-β Agonist, for 28-days in Overweight and Obese Subjects with Elevated LDL-C, a Population with Characteristic s Of NAFLD

The Liver Meeting® 2021 of the American Association for the Study of Liver Diseases (AASLD)

Poster

11/2021